TBI-223   Click here for help

GtoPdb Ligand ID: 13029

Compound class: Synthetic organic
Comment: TBI-223 is an oxazolidinone class antibacterial with potent antimycobacterial activity. It is being clinically evaluated as a treatment for tuberculosis (TB).
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 80.34
Molecular weight 365.36
XLogP 0.57
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES COC(=O)NC[C@H]1CN(C2=CC=C(C(=C2)F)N3CC4(C3)COC4)C(=O)O1
Isomeric SMILES COC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CC4(C3)COC4)F
InChI InChI=1S/C17H20FN3O5/c1-24-15(22)19-5-12-6-21(16(23)26-12)11-2-3-14(13(18)4-11)20-7-17(8-20)9-25-10-17/h2-4,12H,5-10H2,1H3,(H,19,22)/t12-/m0/s1
InChI Key ZNBRXLSWXJKKLJ-LBPRGKRZSA-N
No information available.
Summary of Clinical Use Click here for help
TBI-223 is being developed as an oral treatment for TB and has completed two Phase 1 clinical trials (NCT03758612, NCT04865536) to evaluate its safety, tolerability and pharmacokinetics in healthy adults.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03758612 A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults Phase 1 Interventional Global Alliance for TB Drug Development
NCT04865536 Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects Phase 1 Interventional Global Alliance for TB Drug Development